UNSPSC 51162105: Ethambutol/isoniazid/rifampicin

Definition: This classification is for a combination medication for TB treatment. The first component, ETHAMBUTOL, has US FDA Unique Ingredient Identifier of 8G167061QZ. ETHAMBUTOL is an International Non-Proprietary Name or INN. The second component, ISONIAZID, has US FDA Unique Ingredient Identifier of V83O1VOZ8L. ISONIAZID is an International Non-Proprietary Name or INN. The third component, RIFAMPICIN, has US FDA Unique Ingredient Identifier of VJT6J7R4TR. RIFAMPICIN is an International Non-Proprietary Name or INN.

UNSPSC 51162105 Ethambutol/isoniazid/rifampicin is a Commodity code that names a specific anti-tuberculosis drug combination, but the recent state and local contract opportunities tagged under this code show minimal relevant procurement activity. Of the twenty posted opportunities, only one—Seminole County, Florida's IFB60459723LAS for Naloxone and Drug Deactivation Systems (posted June 30, 2026, response due July 26, 2023)—involves pharmaceutical procurement, and that opportunity addresses opioid-use disorder rather than tuberculosis treatment. The remaining records include a county office relocation notice, vendor networking events and trade shows across Florida and Texas, a forensic drug-standards procurement unrelated to TB therapeutics, employee wellness clinic services, engineering services, a grant solicitation for opioid settlement funds, peer-support workforce services, a pharmacy benefits network RFQ, medical oxygen cylinder rental, and vendor survey feedback—none of which align with the procurement or distribution of ethambutol/isoniazid/rifampicin combinations.

The code appears to see no active state or local government solicitation volume for TB pharmaceutical treatment at present. While state health departments, county public health offices, and transit authorities occasionally procure medications through cooperative purchasing vehicles and open RFPs, this particular drug combination is not appearing in recent posted opportunities across the jurisdictions represented in the source data (primarily Florida, Texas, Minnesota, Arkansas, Arizona, and California). Vendors evaluating pursuit under this code should treat it as a watch category pending future activity; no representative recent solicitation exists to guide market entry or competitive positioning.